Interstitial cystitis/bladder pain syndrome: The evolving landscape, animal models and future perspectives
- PMID: 32246572
- PMCID: PMC7768977
- DOI: 10.1111/iju.14229
Interstitial cystitis/bladder pain syndrome: The evolving landscape, animal models and future perspectives
Abstract
Interstitial cystitis/bladder pain syndrome is a debilitating condition of unknown etiology characterized by persistent pelvic pain with lower urinary tract symptoms and comprises a wide variety of potentially clinically useful phenotypes with different possible etiologies. Current clinicopathological and genomic evidence suggests that interstitial cystitis/bladder pain syndrome should be categorized by the presence or absence of Hunner lesions, rather than by clinical phenotyping based on symptomatology. The Hunner lesion subtype is a distinct inflammatory disease with proven bladder etiology characterized by epithelial denudation and enhanced immune responses frequently accompanied by clonal expansion of infiltrating B cells, with potential engagement of infection. Meanwhile, the non-Hunner lesion subtype is a non-inflammatory disorder with little evidence of bladder etiology. It is potentially associated with urothelial malfunction and neurophysiological dysfunction, and frequently presents with somatic and/or psychological symptoms, that commonly result in central nervous sensitization. Animal models of autoimmune cystitis and neurogenic sensitization might serve as disease models for the Hunner lesion and non-Hunner lesion subtypes, respectively. Here, we revisit the taxonomy of interstitial cystitis/bladder pain syndrome according to current research, and discuss its potential pathophysiology and representative animal models. Categorization of interstitial cystitis/bladder pain syndrome based on cystoscopy is mandatory to design optimized treatment and research strategies for each subtype. A tailored approach that specifically targets the characteristic inflammation and epithelial denudation for the Hunner lesion subtype, or the urothelial malfunction, sensitized/altered nervous system and psychosocial problems for the non-Hunner lesion subtype, is essential for better clinical management and research progress in this complex condition.
Keywords: animal model; autoimmune cystitis; bladder pain syndrome; interstitial cystitis; pathophysiology.
© 2020 The Japanese Urological Association.
Conflict of interest statement
Conflict of interest
None declared.
Figures






Similar articles
-
Phenotyping of interstitial cystitis/bladder pain syndrome.Int J Urol. 2019 Jun;26 Suppl 1:17-19. doi: 10.1111/iju.13969. Int J Urol. 2019. PMID: 31144756 Review.
-
Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesion: A Review and Future Perspectives.Diagnostics (Basel). 2021 Nov 30;11(12):2238. doi: 10.3390/diagnostics11122238. Diagnostics (Basel). 2021. PMID: 34943475 Free PMC article. Review.
-
Clinical guidelines for interstitial cystitis/bladder pain syndrome.Int J Urol. 2020 Jul;27(7):578-589. doi: 10.1111/iju.14234. Epub 2020 Apr 14. Int J Urol. 2020. PMID: 32291805
-
Clinical Phenotyping Does Not Differentiate Hunner Lesion Subtype of Interstitial Cystitis/Bladder Pain Syndrome: A Relook at the Role of Cystoscopy.J Urol. 2016 Oct;196(4):1136-40. doi: 10.1016/j.juro.2016.04.067. Epub 2016 Apr 23. J Urol. 2016. PMID: 27117441
-
Hunner lesion versus non-Hunner lesion interstitial cystitis/bladder pain syndrome.Int J Urol. 2019 Jun;26 Suppl 1:26-34. doi: 10.1111/iju.13971. Int J Urol. 2019. PMID: 31144757 Review.
Cited by
-
Comprehensive transcriptome profiling of urothelial cells following TNFα stimulation in an in vitro interstitial cystitis/bladder pain syndrome model.Front Immunol. 2022 Aug 15;13:960667. doi: 10.3389/fimmu.2022.960667. eCollection 2022. Front Immunol. 2022. PMID: 36045687 Free PMC article.
-
Activation of GPR18 by Resolvin D2 Relieves Pain and Improves Bladder Function in Cyclophosphamide-Induced Cystitis Through Inhibiting TRPV1.Drug Des Devel Ther. 2021 Nov 15;15:4687-4699. doi: 10.2147/DDDT.S329507. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34815664 Free PMC article.
-
Urological Tumor: A Narrative Review of Tertiary Lymphatic Structures.Urol Int. 2023;107(9):841-847. doi: 10.1159/000532127. Epub 2023 Sep 28. Urol Int. 2023. PMID: 37769625 Free PMC article. Review.
-
Serpina3n/serpina3 alleviates cyclophosphamide-induced interstitial cystitis by activating the Wnt/β-catenin signal.Int Urol Nephrol. 2023 Dec;55(12):3065-3075. doi: 10.1007/s11255-023-03726-7. Epub 2023 Aug 18. Int Urol Nephrol. 2023. PMID: 37594700 Free PMC article.
-
Scrotal Pain after Varicocelectomy: A Narrative Review.Biomedicines. 2023 Apr 1;11(4):1070. doi: 10.3390/biomedicines11041070. Biomedicines. 2023. PMID: 37189688 Free PMC article. Review.
References
-
- Hanno PM, Erickson D, Moldwin R, Faraday MM. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J. Urol 2015; 193: 1545–53. - PubMed
-
- Homma Y, Ueda T, Tomoe H et al. Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015. Int. J. Urol 2016; 23: 542–9. - PubMed
-
- van de Merwe JP, Nordling J, Bouchelouche P et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur. Urol 2008; 53: 60–7. - PubMed
-
- Akiyama Y, Hanno P. Phenotyping of interstitial cystitis/bladder pain syndrome. Int. J. Urol 2019; 26(Suppl 1): 17–9. - PubMed
-
- Peeker R, Fall M. Toward a precise definition of interstitial cystitis: further evidence of differences in classic and nonulcerdisease. J. Urol 2002; 167:2470–2. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical